Researchers at the Mayo Clinic have developed an artificial intelligence system capable of detecting early signs of pancreatic cancer up to three years before doctors would normally diagnose the disease. The AI model, called REDMOD (Radiomics-based Early Detection Model), analyzes routine abdominal CT scans and identifies subtle biological changes in the pancreas that are often invisible to the human eye. According to research published in the journal Gut, the system detected early abnormalities in scans that had originally been interpreted as normal.
Pancreatic cancer is considered one of the deadliest forms of cancer because it is usually discovered only after it has spread to other organs. Current five-year survival rates remain extremely low, largely due to the lack of effective early screening tools. In the Mayo Clinic study, the AI model analyzed nearly 2,000 CT scans and identified around 73% of prediagnostic pancreatic cancer cases, often more than a year before clinical diagnosis. Researchers said the system performed roughly three times better than radiologists at spotting very early warning signs.
Scientists believe the AI works by recognizing tiny structural and tissue-texture changes linked to the earliest stages of cancer development. One major breakthrough is its ability to detect abnormal supportive cells around tumors before a measurable mass forms. Researchers suggest the technology could eventually be used for high-risk individuals, including patients with family histories of pancreatic cancer, diabetes, or chronic pancreatic disease. However, experts caution that the model is still being evaluated in long-term clinical trials and is not yet ready for widespread public screening.
The development reflects a broader trend of AI becoming increasingly important in medical imaging and diagnostics. Alongside imaging-based systems, scientists are also developing AI-assisted blood tests and biomarker screening methods for earlier pancreatic cancer detection. Discussions across medical and research communities describe the breakthrough as one of the most promising recent advances in the fight against a disease that has historically been extremely difficult to catch early enough for effective treatment.
